ClinicalTrials.gg
CompletedNCT00500656FAST2Updated Jun 9, 2021Results posted

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)

A Phase 3 interventional study of Icatibant and Tranexamic Acid in Hereditary Angioedema, sponsored by Shire. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Mar 2005, registered Jul 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
3rd of 10
85 · median 26
Started
2005
the only one that year
Phase 3
7 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 3rd largest by enrollment, is the only one that started in 2005, is one of 7 in phase 3, and was the 2nd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

Primary Outcome Measures:

The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid refers to the hazard rate under tranexamic acid.

Secondary Outcome Measures:

  • Additional efficacy assessments (Time to Almost Complete Symptom Relief)
  • Safety and tolerability
  • Pharmacoeconomics
Read the detailed description

This was a Phase III, randomised, double blind, double dummy, multicentre, controlled,parallel group study of a 30 mg s.c. formulation of icatibant for the treatment of patients with moderate to very severe symptoms of cutaneous and/or abdominal symptoms of HAE.

The study consisted of two parts: controlled phase and OLE phase. For the primary endpoint, Efficacy was determined by evaluating the differences in study outcomes using a Visual Analogue Scale for patients treated with icatibant and tranexamic acid.

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 18 years;
  • Documented diagnosis of HAE Type I or II (confirmed C1-INH deficiency);
  • Current edema in the cutaneous, abdominal and/or laryngeal areas;
  • Current edema moderate to severe according to the investigator's Symptom Score.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of angioedema other than HAE,
  • Participation in a clinical trial of another medicinal product (IMP)within the past month
  • Treatment with any pain medication since onset of the current angioedema attack
  • Treatment with replacement therapy, including C1-INH products, less than 3 days before onset of the current angioedema attack
  • Treatment with Tranexamic acid replacement therapy within a week before onset of the current angioedema attack
  • Treatment with ACE inhibitors
  • for Tranexamic acid
  • Evidence of coronary artery disease based on medical history or Screening examination in particular unstable angina pectoris or severe coronary heart disease
  • Congestive heart failure (class 3 and 4)
  • Serum creatinine level of ≥ 250 μmol/L
  • Serious concomitant illness that the investigator considered to be a contraindication for participation in the trial
  • Pregnancy (as assessed prior to treatment) and/or breast-feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Randomized controlled -Icatibant

    Subjects received S.C icatibant+ oral placebo Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL) Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart

    Drug: Icatibant · Drug: Oral Placebo

  • Active comparator
    Randomized controlled-Tranexamic acid

    Subjects received oral Tranexamic acid+ S.C. placebo Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region

    Drug: Tranexamic Acid · Drug: S.C. Placebo

  • Experimental
    Controlled Open-label / laryngeal attack

    Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.

    Drug: Icatibant

  • Experimental
    Untreated patients at the baseline

    Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant

    Drug: Icatibant

Interventions

  • Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.

    Also known as: Brand name, Firazyr®

  • over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.

  • DrugOral Placebo

    hard capsule matched to tranexamic acid

    Also known as: Placebo

  • DrugS.C. Placebo

    solution for injection, matched to icatibant for injection

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Time to Onset of Symptom Relief.

    The primary efficacy endpoint was Time to onset of symptom relief (TOSR) following treatment with either icatibant or tranexamic acid. The median time to onset of symptom relief for the icatibant group was compared to the the median time to onset of symptom relief for the tranexamic acid group. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.

    Time frame: 2 days

Secondary outcomes

  1. Time to Almost Complete Symptom Relief

    Almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least three consecutive measurements for all symptoms.

    Time frame: 48 hours

07

Results

Posted Jun 9, 2014

Participant flow

Controlled Phase
Participant flow — Controlled Phase
MilestoneRandomized Controlled -IcatibantRandomized Controlled-Tranexamic AcidControlled Open-label / Laryngeal AttackUntreated Patients at the Baseline
Started363838
Completed262820
Not completed101018
Open Label Extension (OLE) Phase
Participant flow — Open Label Extension (OLE) Phase
MilestoneRandomized Controlled -IcatibantRandomized Controlled-Tranexamic AcidControlled Open-label / Laryngeal AttackUntreated Patients at the Baseline
Started232128
Completed16916
Not completed71212

Outcome measures

PrimaryTime to Onset of Symptom Relief.

The primary efficacy endpoint was Time to onset of symptom relief (TOSR) following treatment with either icatibant or tranexamic acid. The median time to onset of symptom relief for the icatibant group was compared to the the median time to onset of symptom relief for the tranexamic acid group. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.

Time frame:
2 days
Reported as:
Median · Hours
Time to Onset of Symptom Relief.
HoursRandomized Controlled -IcatibantRandomized Controlled-Tranexamic Acid
Time to Onset of Symptom Relief.2.0 (1.0 to 3.5)12.0 (3.5 to 25.4)
Statistical analysis
  • Randomized Controlled -Icatibant vs Randomized Controlled-Tranexamic Acid · The Wilcoxon version of the log rank · p = < 0.001 · Hazard ratio (hr): 3.475 · 95% CI 1.901 to 6.355The median time to onset was calculated using Kaplan Meier methodology. The Wilcoxon version of the log rank test of SAS was used
SecondaryTime to Almost Complete Symptom Relief

Almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least three consecutive measurements for all symptoms.

Time frame:
48 hours
Reported as:
Median · Hours
Time to Almost Complete Symptom Relief
HoursRandomized Controlled -IcatibantRandomized Controlled-Tranexamic Acid
Time to Almost Complete Symptom Relief10.0 (2.8 to 23.2)51.0 (12.0 to 79.5)
Statistical analysis
  • Randomized Controlled -Icatibant vs Randomized Controlled-Tranexamic Acid · The Wilcoxon version of the log rank · p = < 0.001The median time to almost complete symptom relief was calculated using Kaplan Meier methodology.The Wilcoxon version of the log rank test SAS was used

Adverse events

Collected over An AE was assigned to the controlled phase if the start date of the event was between the first treatment of the first attack and the first treatment in the OLE phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Controlled Phase- Icatibant (Randomized Subjects )—4/36 (11.1%)19/36 (52.8%)
Controlled Phase- Tranexamic Acid (Randomized Subjects)—1/38 (2.6%)16/38 (42.1%)
Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)—1/3 (33.3%)1/3 (33.3%)
Open Label Extension Phase- Icatibant (Previously Randomized)—9/44 (20.5%)31/44 (70.5%)
Open Label Extension Phase (Subjects w/ Laryngeal Attack)—1/2 (50%)1/2 (50%)
Open Label Extension Phase(Untreated Patients at the Baseline—0/8 (0%)4/8 (50%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventControlled Phase- Icatibant (Randomized Subjects )Controlled Phase- Tranexamic Acid (Randomized Subjects)Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)Open Label Extension Phase- Icatibant (Previously Randomized)Open Label Extension Phase (Subjects w/ Laryngeal Attack)Open Label Extension Phase(Untreated Patients at the Baseline
Hereditary AngioedemaCongenital, familial and genetic disorders2/360/381/33/441/20/8
GastroenteritisInfections and infestations1/360/380/32/440/20/8
CholelithiasisHepatobiliary disorders1/360/380/30/440/20/8
CystitisInfections and infestations1/360/380/30/440/20/8
Hypertensive CrisisVascular disorders1/360/380/30/440/20/8
Aortic Value SclerosisCardiac disorders0/361/380/30/440/20/8
Sudden Cardiac DeathGeneral disorders0/361/380/30/440/20/8
Coronary Artery DiseaseCardiac disorders0/360/380/31/440/20/8
Head InjuryInjury, poisoning and procedural complications0/360/380/31/440/20/8
Road Traffic AccidentInjury, poisoning and procedural complications0/360/380/31/440/20/8
Most frequent other events
Showing 10 of 15
Most frequent other events
EventControlled Phase- Icatibant (Randomized Subjects )Controlled Phase- Tranexamic Acid (Randomized Subjects)Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)Open Label Extension Phase- Icatibant (Previously Randomized)Open Label Extension Phase (Subjects w/ Laryngeal Attack)Open Label Extension Phase(Untreated Patients at the Baseline
Hereditary AngioedemaCongenital, familial and genetic disorders10/366/381/310/441/21/8
Gingival InfectionInfections and infestations0/360/380/30/441/20/8
Urinary Track InfectionInfections and infestations0/360/380/36/440/20/8
Dental CariesInfections and infestations0/360/380/30/440/21/8
Respiratory Track InfectionInfections and infestations0/360/380/31/440/21/8
DizzinessNervous system disorders0/360/380/30/440/21/8
PruritusSkin and subcutaneous tissue disorders0/360/380/30/440/21/8
Dental OperationSurgical and medical procedures0/360/380/30/440/21/8
NasopharyngitisInfections and infestations2/363/380/34/440/20/8
Injury, poisoning and procedual complicationsInjury, poisoning and procedural complications3/361/380/33/440/20/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomized Controlled -IcatibantRandomized Controlled-Tranexamic AcidControlled Open-label / Laryngeal AttackUntreated Patients at the BaselineTotal
Mean40.4 ± 13.5941.9 ± 12.3635.0 ± 11.3640.6 ± 13.5140.9 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Controlled -IcatibantRandomized Controlled-Tranexamic AcidControlled Open-label / Laryngeal AttackUntreated Patients at the BaselineTotal
Female24231755
Male12152130
Region of Enrollment
Region of Enrollment(Participants)Randomized Controlled -IcatibantRandomized Controlled-Tranexamic AcidControlled Open-label / Laryngeal AttackUntreated Patients at the BaselineTotal
Austria34018
France31026
Germany13120025
Hungary33006
Ireland01001
Israel443415
Italy35019
Lithuania12003
Poland12003
Sweden32005
Switzerland22004
08

Study locations

1 site
  • Università degli Studi di Milano, Dipartimento di Medicina Interna
    Milano, 20123, Italy
09

References and documents

Publications

  • Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy. 2006 Dec;61(12):1490-2. doi: 10.1111/j.1398-9995.2006.01197.x. No abstract available. PubMed 17073887 ↗
  • Bas M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy. 2013 Nov;68(11):1452-9. doi: 10.1111/all.12244. Epub 2013 Sep 21. PubMed 24111645 ↗
  • Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anne S, Bjorkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hebert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernandez Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum In: N Engl J Med. 2010 Oct 7;363(15):1486. PubMed 20818888 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2005 to primary completion in Jul 2006, 16 months.

Results were first posted in Jun 2014, 7 years 10 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2007
First posted
Jul 13, 2007
StartActual
Mar 1, 2005
Primary completionActual
Jul 25, 2006
CompletionActual
Jul 25, 2006
Results first posted
Jun 9, 2014
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00500656
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 13, 2007
Start date
Mar 1, 2005
Primary completion
Jul 25, 2006
Completion
Jul 25, 2006
Results posted
Jun 9, 2014
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion